Systemic lupus erythematosus (SLE) is the prototypic autoimmune condition, often affecting multiple organ systems, including the skin. Cutaneous lupus erythematosus (CLE) is distinct from SLE and may be skin limited or associated with systemic disease. Histopathologically, the hallmark of lupus-specific manifestations of SLE and CLE is an interface dermatitis. The cause of SLE and CLE is likely multifactorial and may include shared genetic factors. In this review, we will discuss the genetic findings related to the cutaneous manifestations of SLE and isolated CLE, with a particular focus on the lupus-specific CLE subtypes.
INTRODUCTION
Systemic lupus erythematosus (SLE) is the prototypic autoimmune condition, characterized by the production of autoantibodies leading to organspecific inflammation and damage. SLE can involve multiple organ systems, including the skin. Cutaneous manifestations of SLE are common, affecting up to 75% of patients with SLE, and may be the first sign of disease in 25% of patients [1] . In the 1997 American College of Rheumatology (ACR) classification criteria for SLE, four of the possible 11 criteria for diagnosing SLE are mucocutaneous manifestations (malar rash, discoid rash, photosensitivity, and nasal/oral ulcerations). The recently updated Systemic Lupus Collaborating Clinics classification criteria for SLE diagnosis broadens the potential cutaneous manifestations of SLE to include all subtypes of cutaneous lupus erythematosus (CLE), including acute CLE (ACLE) (e.g., bullous lupus, the toxic epidermal necrolysis variant of ACLE ), subacute CLE (SCLE), chronic CLE (CCLE) (e.g., discoid lupus, lupus panniculitis, lupus erythematosus tumidus, and chilblain lupus), nasal/oral ulcerations, and nonscarring alopecia [2] . Some patients have isolated CLE, which is distinct from SLE. The incidence of CLE is 4.3/100 000, which is comparable with the incidence of SLE [3] . Not all patients with isolated CLE progress to develop SLE, but population-based studies have suggested a frequency of evolution ranging from 0 to 28%, with an interval between onset of cutaneous disease and SLE diagnosis ranging from months to 30þ years [3, 4, 5 in children suggest a rate of progression to SLE that approaches 30%, with limited duration of follow-up [6 & ]. CLE is typically divided into lupus-specific and lupus-nonspecific manifestations, with lupusspecific disease demonstrating distinct histopathology for lupus, including vacuolar interface dermatitis ( Fig. 1 ). Lupus-nonspecific skin lesions are not histopathologically distinct for lupus and may be seen as a reactive feature of another disease process (Table 1) . When present in patients with SLE, lupusnonspecific skin disease is often a marker for active systemic disease [7, 10] .
Lupus-specific disease encompasses four different subtypes: ACLE, SCLE, CCLE, and a recently defined entity, intermittent CLE, which now includes lupus erythematosus tumidus. These subtypes are primarily distinguished by clinical morphology and histologic findings [11] . Skin biopsy is often helpful as the many variants of CLE can mimic other diseases, and recognition of the specific subset may help to prognosticate risk of developing SLE. A validated scoring system called the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) was created as a skinspecific outcome instrument to score disease activity and damage in three specific subtypes of CLE [ACLE, SCLE, and discoid lupus erythematosus (DLE)] [12] . Clinical trials in CLE are still uncommon but use of precise outcome instruments may help to determine organ-specific cutaneous response to therapy.
CLE can lead to scarring and dyspigmentation in cosmetically sensitive areas, including the face and scalp. Isolated CLE is associated with psychological stress, occupational disability, and severely impaired quality of life. One study demonstrated that patients with CLE experience a poorer quality of life than other common dermatologic conditions, including acne, alopecia, and skin cancer, and shoulder a mental health burden that matches or exceeds those with chronic hypertension, type 2 diabetes mellitus, recent myocardial infarction, and congestive heart failure [13] . Importantly, quality of life directly correlates with skin disease activity rather than damage, and improves with treatment, suggesting that early intervention may significantly impact psychological burden in this disease [14,15 && ]. Finally, disease activity, and not markers of damage, including scarring and dyspigmentation, correlates most strongly with impaired quality of life, suggesting that early therapeutic intervention may significantly impact psychological burden in this disease [15 && ]. The cause of SLE and CLE is likely to be multifactorial and has been attributed to an interaction between multiple genetic and environmental factors [16 & ]. Over the past decade, there has been significant interest in understanding the genetic underpinnings of SLE and other related autoimmune conditions. The higher incidence of SLE among family members, and particularly between monozygotic twins, would suggest that there is a genetic predisposition to SLE [17] . Numerous studies have demonstrated the increased frequency of certain major histocompatibility complex class I and II alleles [e.g., Human Leukocyte Antigen (HLA)-DR2 and HLA-DR3], single nucleotide polymorphisms (SNPs) in genes that predispose to multiple autoimmune disorders (e.g., protein tyrosine phosphatase, nonreceptor type 22 and signal transducer and activator of transcription 4), as well as variants in genes that are specific to SLE [e.g., integrin alpha M (ITGAM)], although ethnic and population differences may influence these observations [18] . Several studies
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Cutaneous involvement is common in SLE.
There are four subtypes of lupus-specific CLE; histopathologically, the hallmark of lupus-specific manifestations of SLE and CLE is an interface dermatitis.
The cause of SLE and CLE is likely multifactorial but there may be a shared genetic susceptibility. FIGURE 1. Classic histopathology for discoid lupus erythematosus is demonstrated, including hyperkeratosis of the stratum corneum (green arrow), mild thickening of the basement membrane (purple arrows), and vacuolar interface dermatitis at the dermal-epidermal junction (black arrows). There are also lymphoid infiltrates surrounding both blood vessels and eccrine glands in the dermis (red arrows).
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have examined the phenotype/genotype relationship between various SLE disease manifestations and underlying genetic differences. In this manuscript, we will review genetic findings related to the cutaneous manifestations of SLE and isolated CLE, with a particular focus on the lupus-specific CLE subtypes.
GENETICS OF CUTANEOUS MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS
A handful of studies have examined the genotype/ phenotype relationship between specific SLE manifestations and genotype. The current literature suggests that ITGAM polymorphisms are the most common variants associated with skin involvement in SLE [19 && ]. The rs1143679 SNP of ITGAM has been associated with malar rash (ACLE) and discoid lupus [20] . ITGAM encodes the CD11b chain of the Mac-1 integrin, a surface receptor protein involved in the interaction of monocytes, macrophages, and granulocytes. There are several hypotheses as to the role of ITGAM in the pathogenesis of SLE and CLE. One hypothesis is that the production of dysfunctional integrin may prevent cell adhesion and phagocytosis which leads to decreased clearance of extracellular components and increased immune system activation. Specific to the relationship between ITGAM variants and cutaneous lupus, there also appears to be a link between ITGAM and photosensitivity with ITGAM variants altering the response to ultraviolet (UV) B irradiation. Lastly, the absence of CD11b may lead to the differentiation of naïve T cells to IL-17 producing Th17 cells; increased IL-17 levels have been found in the skin lesions of patients with CLE [21] . ITGAM mutations have been associated with several other common manifestations of SLE, including renal disease, arthritis, and antidouble-stranded DNA, Sjogren's syndrome-A and Sjogren's syndrome-B, ribonucleoprotein, and Smith positivity [22] .
Sanchez et al. [22] described an association between a SNP in the Fc Fragment Of IgG, Low Affinity IIa, Receptor (CD32) (FCGR2A) gene (rs1801274) and malar rash in an ethnically heterogeneous cohort of over 8000 SLE patients [odds ratio (OR) 1.11, confidence interval (CI) 1.17-1.33]. FCGR2A encodes an Fc receptor for IgG that is involved in the clearance of immune complexes. The SNP results in an amino acid change that in turn results in the generation of an Fc-g receptor with altered binding to IgG subclasses.
Variants in the vitamin D receptor gene have also been implicated in susceptibility to cutaneous manifestations of SLE. Vitamin D appears to play a critical role in the prevention of UV-induced DNA damage; photosensitivity and the eruption of erythematous rashes is a well described phenomenon in SLE patients. In a Brazilian population of SLE patients, the rs11168268 vitamin D receptor mutation was associated with 'cutaneous alterations' [23] . In this same Brazilian population, the rs7805969 polymorphism in the Serine/Threonine Kinase 17a gene, a DNA repair-related gene, was associated with cutaneous manifestations of SLE [24] .
Interleukin-6 (IL-6) is a proinflammatory cytokine which plays a potential pathogenic role in many inflammatory disorders. Prior studies on the relationship between IL-6 polymorphisms and SLE were inconclusive. To address this, Cui et al. performed a meta-analysis of 15 association studies, and also performed ethnicity-specific meta-analysis in European, Iranian, and Asian populations. They found a significant association between a polymorphism in the promoter region of the IL-6 gene (À174 G/C SNP; rs1800795) and discoid skin lesions (OR 2.27, 95% CI 1.05-4.9), supporting a role for this variant in susceptibility to cutaneous manifestations of SLE [25] .
GENETICS OF CUTANEOUS LUPUS ERYTHEMATOSUS
Major histocompatibility complex associations
The relationship between CCLE and HLA class II alleles, specifically HLA DQA1, were initially described by Fischer et al. [26] in 1994 in a small cohort of 26 patients with CCLE compared with healthy controls. The presence of DQA1Ã0102 in patients was associated with a 4.6-fold increase of CCLE, which was statistically significant after correcting for multiple comparisons. HLA DRB1Ã16 is in linkage disequilibrium with HLA-DQA1Ã0102, and was also observed at an increased frequency, but this association was not significant after correction for multiple comparisons. In another study of 85 Caucasian patients with annular SCLE and DLE, Millard et al. [27] found a higher frequency of HLA AÃ01, BÃ08, and DRB1Ã0301 alleles in patients compared with controls, as well as a significant association between the HLA AÃ03, BÃ07, and the DRB1Ã15 haplotypes and DLE. This study also investigated for symptoms of polymorphic light eruption (PLE), an inherited disorder of photosensitivity in patients, their relatives, and healthy controls. An association between PLE and cutaneous lupus erythematosus was found (P < 0.001) independent of HLA association. The estimated relative risk of SCLE given the presence of PLE, DRB1Ã0301, and both was 3.37, 5.45, and 12.03, respectively, demonstrating that there may be shared susceptibility to photosensitivity and cutaneous lupus erythematosus.
A recent genome-wide association study identified four novel susceptibility loci for CLE [28 & ]. In this study, 183 CLE cases [CCLE 44.8%, SCLE 40.4%, and intermittent CLE (lupus erythematosus tumidus) 14 .2%] and 1288 controls of Central European ancestry were genotyped for over 90 000 SNPs. Replication was performed in 219 study participants and 262 controls from a Finnish cohort. The four SNPs that reached genome-wide significance (rs2187668, rs9267531, rs4410767, and rs2187668) were all located within the major histocompatibility complex region of chromosome 6 and close to genes involved in various aspects of immune system functioning, including antigen presentation, apoptosis regulation, DNA processing, and the interferon response 
NONMAJOR HISTOCOMPATIBILITY COMPLEX ASSOCIATIONS
Complement deficiency
An association between complement deficiency and photosensitivity was initially described in 1979 by Levy et al. [29] in a 59-year-old patient with autosomal recessive inheritance of C2 deficiency. Discoid lupus erythematosus has been demonstrated in individual and familial cases of C4 deficiency [30, 31] . More recently, Racila et al. [32] described the association between SCLE and a homozygous SNP of the gene Complement Component 1, Q Subcomponent, A Chain (C1QA), which encodes complement component 1, subcomponent q, resulting in decreased levels of C1Q. Finally, combined partial deficiencies of C2 and C4 were reported in a cohort of adult French patients with CCLE and SCLE in the absence SLE. As most of these patients were smokers, tobacco exposure was hypothesized to be a risk factor for precipitation of their cutaneous disease [33] .
TREX1 mutations
Mutations in the Three Prime Repair Exonuclease 1(TREX1) gene are associated with a rare form of CLE called familial chilblain lupus [34] . Patients with this condition develop painful violaceous nodules, typically on the fingers and toes, that may ulcerate.
Patients often have systemic symptoms, including neurologic symptoms, as seen in Aicardi-Goutieres syndrome, another syndrome related to dysfunction in the TREX1 gene [35] . TREX1 is an intracellular DNAase; deficiency in TREX1 leads to accumulation of components of intracellular DNA which are thought to activate the immune system and lead to autoimmunity.
As with SLE, the ITGAM rs1143679 variant has been associated with isolated CLE, specifically DLE, which is a subtype of CCLE. In a cohort of Finnish and Swedish patients with DLE without signs of systemic disease, there was a significant association with the ITGAM rs1143679 variant [OR 3.2 (95% CI 2.23-4.57)] [36] .
Not surprisingly, other genes implicated in the pathogenesis of SLE have also shown significance in patients with isolated CLE. In a Finnish population with DLE or SCLE, the tyrosine kinase 2 rs2304256 SNP was associated with an increased risk of DLE (P ¼ 0.012, OR ¼ 1.47, 95% CI ¼ 1.01-1.98) [37] . The tyrosine kinase receptor plays a role in interferon signaling; interferon appears to be critical in the pathogenesis of SLE [38] . In the same cohort, the interferon regulatory factor 5 polymorphism rs10954213 was associated with DLE (P ¼ 0.017, OR ¼ 1.4, 95% CI 1.06-1.86) and SCLE (P ¼ 0.022, OR ¼ 1.87, 95% CI 1.09-3.21). The interferon regulatory factor 5 gene encodes a group of transcription factors which are involved in virus-mediated activation of interferon, modulation of cell growth, apoptosis, and immune system activation. A haplotype of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) showed association with DLE (P ¼ 0.0064, OR ¼ 2.51, 95% CI 1.25-5.04). CTLA4 is a protein-coding gene that transmits an inhibitory signal to T cells. CTLA4 polymorphisms have been associated with multiple autoimmune conditions, including SLE, type I diabetes mellitus, Graves' disease, Hashimoto thyroiditis, and celiac disease, and CTLA4 deficiency may lead to significant immune dysregulation [39] .
CONCLUSION
Several genetic polymorphisms have been identified which may contribute to the cutaneous manifestations of SLE and to CLE. Most of these genetic variants are involved in pathways well described in the pathogenesis of SLE, including the roles of interferon, vitamin D regulation, and UV light exposure. Although there is overlap between the genetic factors associated with SLE and CLE, there appear to be unique genetic factors specific for CLE. Better understanding of the genetics of CLE may lead to the creation of targeted therapies, improving outcomes for patients with this challenging dermatologic condition.
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